Control rEaGH cND cND-rEaGH
20. 劉威志, (2005) 物理雙月刊科學普及選輯-從奈米到宇宙, 23 卷, 175-183
21. Ginsberg, M. S., Grewal, R. K., Heelan, R. T. (2007) Lung cancer. Radiol. Clin.
North. Am. 45, 21-43.
22. Shibuya, K., Hoshino, H., Chiyo, M., Iyoda, A., Yoshida, S., Sekine, Y., Iizasa, T., Saitoh, Y., Baba, M., Hiroshima, K., Ohwada, H., and Fujisawa, T. (2003) High magnification bronchovideoscopy combined with narrow band imaging could detect capillary loops of angiogenic squamous dysplasia in heavy smokers at high risk for lung cancer. Thorax. 58, 989-995.
23. Waidhauser, E., Beck. O. J., Oeckler, R. C. (1990) Nd:YAG-laser in the microsurgery of frontobasal meningiomas. Lasers Surg. Med. 10, 544-550.
24. Nowis, D., Legat, M., Grzela, T., Niderla, J., Wilczek, E., Wilczynski, G. M., Głodkowska, E., Mrówka, P., Issat, T., Dulak, J., Józkowicz, A., Waś, H., Adamek, M., Wrzosek, A., Nazarewski, S., Makowski, M., Stokłosa, T., Jakóbisiak, M., and Gołab, J. (2006) Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene. 25, 3365-3374.
25. Moriwaki, S. I, Misawa, J., Yoshinari, Y., Yamada, I., Takigawa, M., Tokura, Y.
(2001) Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin).Photodermatol.
Photoimmunol. Photomed. 17, 241-243.
26. Nowis, D., Makowski, M., Stokłosa, T., Legat, M., Issat, T., and Gołąb, J. (2005) Direct tumor damage mechanisms of photodynamic therapy. 52, 339-352.
27. Baselga, J. (2007) Why the Epidermal Growth Factor Receptor? The Rationale for
Cancer Therapy. Oncologist. 7, 2-8.
28. Schmidt, M., Reiser, P., Hills, D. et al. (1998) Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int. J. Cancer. 75,878-884.
29. Schmidt, M., Maurer-Gebhard, M., Groner, B. et al. (1999) Suppression of metastasis formation by a recombinant single chain antibody- toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene. 18, 1711-1721.
30. Gonzalez, G., Crombet, T., Catala, M. et al. (1998) A novel cancer vaccine
composed of human-recombinant epidermal growth factor linked to a carrier protein:
report of a pilot clinical trial. Ann. Oncol. 9, 431-435.
31. Nel, A., Xia T., Ma¨dler, L., and Li, N. (2006) Toxic potential of materials at the nanolevel. Science. 3, 622-627.
32. Silva, G. A. (2007) Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg. Neurol. 67, 113-116.
33. Oberdörster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J.,
Ausman, K., and etc. (2005) Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre.
Toxicol. 6, 2-8.
34. Chen, X., and Mao, S.S. (2006) Synthesis of titanium dioxide (TiO2) nanomaterials.
J. Nanosci. Nanotechnol. 6, 906-925.
35. Fan, H.J., Knez, M., Scholz, R., Hesse, D., Nielsch, K., Zacharias, M., and Gösele, U. (2007) Influence of surface diffusion on the formation of hollow nanostructures induced by the Kirkendall effect: the basic concept. Nano. Lett. 7, 993-997.
36. Pitkethly, Michael J. (2004) Nanomaterials – the driving force. Materials Today 7, 20-29.
37. Narayanan, R., and E1-Sayed M. A., (2005) Catalysis with transition metal nanoparticles in colloidal solution: nanoparticle shape dependence and stability.
J. Phys. Chem. B. 109, 12663-12676.
38. Schmidt, M., Kusche, R., Issendorff, B. V., and Haberland, H. (1998) Irregular variations in the melting point of size-selected atomic clusters. Nature. 393, 238-240.
39. Cheon, J., Park, J. I., Choi, J. S., Jun, Y. W., Kim, S,, Kim, M.G., Kim, Y. M., and Kim, Y. J. (2006) Magnetic superlattices and their nanoscale phase transition effects.
Proc. Natl. Acad. Sci. U S A. 103, 3023-3027.
40. Hammer, B., and Norskov, J. K. (1995) Why gold is the noblest of all the metals.
Nature. 376, 238-24011.
41. Zhu, B., Angelici, R. J. (2006) Non-nanogold catalysis of carbon monoxide oxidative amination. J. Am. Chem. Soc. 128, 14460-14461.
42. Kapoor, M. P., Sinha, A. K., Seelan, S., Inagaki, S., Tsubota, S., Yoshida, H., and
Haruta, M. (2002) Hydrophobicity induced vapor-phase oxidation of propene over gold supported on titanium incorporated hybrid mesoporous silsesquioxane
Chem. Commun. 23, 2902-2903.
43. Claus, P., Bruckner, A., Mohr, C., and Hofmeister, H. (2000) Supported Gold Nanoparticles from Quantum Dot to Mesoscopic Size Scale: Effect of Electronic and Structural Properties on Catalytic Hydrogenation of Conjugated Functional Groups. J. Am. Chem. Soc. 122, 11430-11439.
44. Mohr, C., Hofmeister, H., Radnik, J., and Claus, P. (2003) Identification of Active Sites in Gold-Catalyzed Hydrogenation of Acrolein. J. Am. Chem. Soc. 125, 1905-1911.
45. Glinka, Yu. D., Lin, K.-W., and Lin, S. H. (1999) Multiphoton-excited luminescence from diamond nanoparticles and an evolution to emission accompanying the laser vaporization process. Appl. Phys. Lett. 74, 236-23811.
46. Khabashesku, V. N., Margrave, J. L., and Barrera, E. V. (2005) Functionalized carbon nanotubes and nanodiamonds for engineering and biomedical applications.
Diamond & Related Materials. 14, 859-866.
47. Mikhaylova, M., Kim, D. K., Berry, C. C., Zagorodni, A., Toprak, M., Curtis, A. S.
G., and Muhammed, M. (2004) BSA immobilization on amine-functionalized superparamagnetic iron oxide nanoparticles. Chem. Mater. 16, 2344-2354.
48. Tu, J.-S., Perevedentseva, E., Chung, P.-H., and Cheng, C.-L. (2006) Size-dependent surface CO stretching frequency investigations on nanodiamond particles. J. Chem.
Phys. 125, 174713-174719.
49. 潘善鵬, 翁漢甫, (2007) 動態光散射儀與奈米粉體粒徑之量測不確定度分析, 機械工業雜誌, 288 期, 95-98.
50. CellTiter 96 aqueous one soluteion cell prolixferation assay. Promega corporation.
51. Tuggle, C. K., and Trenkle, A. (1996) Control of growth hormone synthesis. Domest.
Anim. Endocrinol. 13, 1-33.
52. Emtner, M., Mathews, L. S., and Norstedt, G. (1990) Growth hormone (GH) stimulates protein synthesis in cells transfercted with GH recaptor complementary DNA. Mol. Endocrinol. 4, 2014-2020.
53. Carter-Su, C., Schwartz, J., and Smit, L. S. (1996) Molecular mechanism of growth hormone action. Annu. Rev. Physiol. 58, 187-207.
54. Moriyama, S. (1995) Increased plasma insulin-like growth factor-I (IGF-1) following oral and intraperitoneal administration of growth hormone to rainbow trout, Oncorhynchus mykiss. Growth Regul. 5, 164-167.
55. Sakai, M., Kobayashi, M., and Kawauchi, H. (1996) Mitogenic effect of growth hormone and prolactin on chum salmon Oncorhynchus keta leukocytes in vitro. Vet.
Immunol. Immunopathol. 53, 185-189.
56. Glinka, Yu. D., Lin, K.-W., and Lin, S. H. (1999) Multiphoton-excited
luminescence from diamond nanoparticles. Appl. Phys. Chem. B 103, 4251-4263.
57. Tuggle, C. K., and Trenkle, A. (1996) Control of growth hormone sybthesis. Domest.
Anim. Endocrinol. 13, 1-33.
58. Lee, L. T., Nong, G., Chan, Y. H., Tse, D. L., Cheng, C H. (2001) Molecular cloning of a teleost growth hormone receptor and its functional interaction with human growth hormone. Gene. 270, 121-129.
59. Instructions of EDC, Pierce.
60. Chang. C. C., Tsai, C.-T., and Chang, C.-Y. (2002) Structural restoration of inactive recombineant fish growth hormones by chem.ical chaperonin and solvent restraint approaches. Protein Eng. 15. 437-441.
61. Heinrichs, C., Yanovskit, J. A., Roth, A. H., Yu, M. Y., Domene H. M., Yano, K., Cutler, G., and Baron, J. (1994) Dexamethasone increases growth hormone receptor messenger ribonucleic acid levels in liver and growth plate. Endocrinology. 135, 1113-1118.
62. Hansen, L. H., Wang X., Kopchick, J. J., Bouchelouchei, P., Nielsen, J. H., Galsgaard, E. D., and Billestrup, N. (1996) Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and stat5 activation. J. Biol. Chem. 271, 12669–12673.
63. Jones, C..J., Hartmann, M., Blaschitz, A., and Desoye, G. (1993) Ultrastructural localization of insulin receptors in human placenta. Am. J. Reprod. Immunol. 30, 136–145.
64. Murata, K., Maruo, T., Matsuo, H., and Mochizuki, M. (1994) Insulin-like growth factor-I (IGF-I) as a local regulator of proliferation and differentiation of
villous trophoblasts in early pregnancy. Nippon Sanka Fujinka Gakkai Zasshi 46, 87–94.
65. Ohlsson, R., Holmgren, L., Glaser, A., Szpecht, A., and Pfeifer-Ohlsson, S. (1989) Insulin-like growth factor 2 and short-range stimulatory loops in control of human placental growth. EMBO J. 8, 1993–1999.
66. Florio, P., Franchini, A., Reis, F. M., Pezzani, I., Ottaviani, E., and Petraglia, F.
(2000) Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. Placenta. 21, 32–37.
67. Maruo, T., and Mochizuki, M. (1987) Immunohistochemical localization of epidermal growth factor receptor and myc oncogene product in human placenta, implication for trophoblast proliferation and differentiation. Am. J. Obstet. Gynecol.
156, 721–727.
68. Hofmann, G. E., Drews, M. R., Scott, R.T. Jr., Navot, D., Heller, D., and Deligdisch, L. (1992) Epidermal growth factor and its receptor in human
implantationtrophoblast, immunohistochemical evidence for autocrine/paracrine function. J. Clin. Endocrinol. Metab. 74, 981–988.
69. Sugawara, T., Maruo, T., Otani, T., and Mochizuki, M. (1994) Increase in the expression of c-erbA and c-erbB mRNAs in the human placenta in early
gestation. Their roles in trophoblast proliferation and differentiation. Endocr. J. 41, S127–S133.
70. Maruo, T., Matsuo, H., Otani, T., and Mochizuki, M. (1995) Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta.
Reprod. Fertil. Dev. 7, 1465–1470.
71. Kauma, S., Hayes, N., and Weatherford, S. (1997) The differential expression of hepatocyte growth factor and met in human placenta. J. Clin. Endocrinol. Metab. 82, 949–954.
72. Fairchild Benyo, D., and Conrad, K.P. (1999) Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol. Reprod. 60, 861–870.
73. Athanassiades, A., Hamilton, G. S., and Lala, P. K. (1998) Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol. Reprod. 59, 643–654.
74. Tseng, J. J., Chou, M. M., Hsieh, Y. T., Wen, M. C., Ho, E. S., and Hsu, S. L. (2006) Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by
placenta accreta. Placenta. 27, 70–78.
75. Jokhi, P. P., King, A., Jubinsky, P. T., and Loke, Y.W. (1994) Demonstration of the low affinity alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-R alpha) on human trophoblast and uterine cells. J.
Reprod. Immunol. 26, 147–164.
76. McCracken, S. A., Grant, K. E., MacKenzie, I. Z., Redman, C.W., and Mardon, H. J.
(1999) Gestational regulation of granulocyte-colony stimulating factor receptor expression in the human placenta. Biol. Reprod. 60, 790–796.
77. Fulop, V., Mok, S. C., Genest, D.R., Szigetvari, I., Cseh, I., and Berkowitz, R. S.
(1998) c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J. Reprod. Med. 43, 101–110.
78. Jokhi, P. P., Chumbley, G., King, A., Gardner, L., and Loke, Y. W. (1993) Expression of the colony stimulating factor-1 receptor (c-fms product) by cells at the human uteroplacental interface. Lab. Invest. 68, 308–320.
79. Gurski, M. R., Gonzalez, E., and Brown, E. G. (1999) Immunochemical localization of platelet-derived growth factor in placenta and its possible role in preeclampsia. J.
Invest. Med. 47, 128–133.
80. Nixon, T., Green, H. (1983) Properties of growth hormone receptors in relation to the adipose conversion of 3T3 cells. J. Cell Physiol. 115, 291–296.
81. Zou, L., Burmeister, L. A., and Sperling, M. A. (1997) Isolation of a liverspecific-
promoter for human growth hormone receptor gene. Endocrinology 138,1771–1774.
82. De Mello-Coelho, V., Gagnerault, M. C., Souberbielle, J. C., Strasburger, C. J., Savino, W., Dardenne, M., Postel-Vinay, M. C., (1998) Growth hormone and its receptor are expressed in human thymic cells. Endocrinology 139, 3837–3842.
83. Huang, E., Cheng, S. H., Dressman, H., Pittman, J., Tsou, M. H., Horng, C. F., Bild, A., Iversen, E. S., Liao, M., Chen, C. M. et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet. 361, 1590–1596.
84. Ilvesmaki, V., Kahri, A.I., Miettinen, P. J., and Voutilainen, R. (1993) Insulin-like growth factors (IGFs) and their receptors in adrenal tumours, high IGF-II
expression in functional adrenocortical carcinomas. J. Clin. Endocrinol.
Metab. 77, 852–858.
85. Reubi, J. C., Waser, B., Vale, W., and Rivier, J. (2003) Expression of CRF1 and CRF2 receptors in human cancers. J. Clin. Endocrinol. Metab. 88, 3312–3320.
86. Gschwind, A., Fischer, O. M., and Ullrich, A. (2004) The discovery of receptor tyrosine kinases, targets for cancer therapy. Nat. Rev. Cancer. 4, 361–370.
87. Hynes NE and Lane HA (2005) ERBB receptors and cancer, the complexity of targeted inhibitors. Nat. Rev. Cancer. 5,341–354.
88. Henic, E., Sixt, M., Hansson, S., Hoyer-Hansen, G., and Casslen, B. (2006) EGFstimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol. Oncol. 101, 28–39.
89. Resnick, M. B., Routhier, J., Konkin, T., Sabo, E., and Pricolo, V.E. (2004) Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer, a tissue microarray study. Clin.
Cancer. Res. 10, 3069–3075.
90. Hu, W. G., Liu, T, Xiong, J. X., and Wang, C. Y. (2007) Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin. 28, 1224-30.
91. Zhou, C. C., Zhou, S. W., Pan, H., Su, B., and Gao, Z. Q. (2007) Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes. Zhonghua Zhong Liu Za Zhi.
29,119-123.
92. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G. F. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4, 915–925.
93. Han, S. U., Lee, H. Y., Lee, J.H., Kim, W. H., Nam, H., Kim, H., Cho, Y. K., Kim, M. W., and Lee, K. U. (2005) Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann. Surg. 242, 676–683.
94. Dagnon, K., Pacary, E., Commo, F., Antoine, M., Bernaudin, M., Bernaudin, J. F., and Callard, P. (2005) Expression of erythropoietin and erythropoietin receptor
in non-small cell lung carcinomas. Clin. Cancer. Res. 11, 993–999.
95. Acs, G., Zhang, P. J., Rebbeck, T. R., Acs, P., and Verma, A. (2002)
Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95, 969–981.
96. Meunier-Carpentier, S., Dales, J. P., Djemli, A., Garcia, S., Bonnier, P.,
Andrac-Meyer, L., Lavaut, M. N., Allasia, C., and Charpin, C. (2005) Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor
expression in breast carcinoma. Int. J. Oncol. 26, 977–984.
97. Rivas, C. I., Vera, J. C., Delgado-Lopez, F., Heaney, M. L., Guaiquil, V. H., Zhang, R. H., Scher, H. I., Concha, II., Nualart, F., Cordon-Cardo, C. et al. (1998)
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood 91, 1037–1043.
98. Abdelrahim, M., Baker, C. H., Abbruzzese, J. L., Sheikh-Hamad, D., Liu, S., Cho, S.
D., Yoon, K., and Safe, S. (2007) Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.
Cancer Res. 67, 3286-3294.
99. Yang, X., Liu, F., Xu, Z., Chen, C., Wu, X., Li, G., and Li J (2005) Expression of granulocyte colony stimulating factor receptor in human colorectal cancer. Postgrad.
Med. J. 81, 333–337.
100. Pinto-de-Sousa, J., David, L., Almeida, R., Leitao, D., Preto, J. R., Seixas, M., and Pimenta, A. (2002) c-erb B-2 expression is associated with tumour location
and venous invasion and influences survival of patients with gastric carcinoma.
Int. J. Surg. Pathol. 10, 247–256.
101. Hynes NE and Lane HA (2005) ERBB receptors and cancer, the complexity of targeted inhibitors. Nat. Rev. Cancer. 5, 341–354.
102. Nakano, T., Oka, K., Ishikawa, A., and Morita, S. (1997) Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 79, 513–520.
103. Frutuoso, C., Silva, M. R., Amaral, N., Martins, I., De Oliveira, C., and De Oliveira, H. M. (2001) Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma. Acta. Med. Port. 14, 277–283.
104. Ide, H., Seligson, D.B., Memarzadeh, S., Xin, L., Horvath, S., Dubey, P., Flick, M.
B., Kacinski, B. M., Palotie, A., and Witte, O. N. (2002) Expression of colonystimulating factor 1 receptor during prostate development and prostate cancer progression. Proc. Natl. Acad. Sci. USA 99, 14404–14409.
105. Sapi, E. (2004) The role of CSF-1 in normal physiology of mammary gland and breast cancer, an update. Exp. Biol. Med. (Maywood) 229, 1–11.
106. Yang, D. H., Huang, W., Cui, J., Shu, J. C., Tang, S.H., Zhang, W. J., and Liang, J.
H. (2004) The relationship between point mutation and abnormal expression of
c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 3, 86–89.
107. Smith, H. O., Anderson, P. S., Kuo, D. Y., Goldberg, G. L., DeVictoria, C. L., Boocock, C. A., Jones, J. G., Runowicz, C. D., Stanley ER and Pollard JW (1995) The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin. Cancer. Res. 1, 313–325.
108. Carvalho, I., Milanezi, F., Martins, A., Reis, R. M., and Schmitt, F. (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is
associated with tumour progression. Breast Cancer Res. 7, 788–795.
109. Alonso, M., Galera, M. J., Reyes, G., Calabuig, R., Vinals, A., Rius, X. (1992) Effects of pentagastrin and of the somatostatin analog (SMS 201–995) on growth of CT26 in vivo adenocarcinoma of the colon. Surg. Gynecol. Obstet. 175, 441–444.
110. Dy, D. Y., Whitehead, R. H., Morris, D. L. (1992) SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res. 52, 917–923.
111. Qin, Y., Schally, A. V., Willems, G. (1991) Somatostatin analogue RC-160
inhibits the growth of transplanted colon cancer in rats. Int. J. Cancer. 47, 765–770.
112. Smith, J. P., Solomon, T. E. (1988) Effects of gastrin, proglumide, and
somatostatin on growth of human colon cancer. Gastroenterology 95, 1541–1548.
113. Wagner, K., Hemminki, K., Grzybowska, E., Bermejo, J. L., Butkiewicz, D., Pamula, J., Pekala, W., and Forsti, A. (2006) Polymorphisms in the growth hormone receptor: a case-control study in breast cancer. Int. J. Cancer. 118, 2903-6.
114. Stanimirovic, A., Cupic, H., Bosnjak, B., Tomas, D., Kruslin, B., and Belicza, M.
(2005) TP53, Bcl-2 and growth hormone receptor expression in cutaneous squamous cell carcinoma. Acta. Dermatovenerol. Croat. 13, 201-105.
115. Wust, P., Gneveckow, U., Johannsen, M., Böhmer, D., Henkel, T., Kahmann, F., Sehouli, J., Felix, R., Ricke, J., and Jordan, A. (2006) Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures. Int. J.
Hyperthermia. 22, 673-685.
116. Kong, X. L., Huang, L. C. L., Hsu,C.-M., Chen, W.-H., Han, C.-C., and Chang H.-C. (2005) High-affinity capture of proteins by diamond nanoparticles for mass spectrometric analysis. Anal. Chem. 77, 259-265.
117. Talapatra, S.,Ganesan, P. G.., Kim T., Vajtai R., Huang, M., Shima, M., Ramanath, G.., Srivastava, D., Deevi, S. C., and Ajayan, P. M. (2005) Irradiation-induced magnetism in carbon nanostructures. Phys. Rev. Lett. 95, 097201-097204.
附錄 附錄一 蛋白質復性緩衝液的配方
Tris-base
(mM) pH Urea (M)
DTT (mM)
Pefabloc (mM)
Mannitol (%) Denature
Buffer 10 11 ~ 12 4.5 100 0.5 0.1 Folding
buffer 1 10 11 2 0.1 0.5 0.1
Folding
buffer 2 10 11 1 0.1 0.5 0.1
Folding
buffer 3 10 11 - 0.1 0.5 0.1
Folding
buffer 4 10 8.8 - 0.1 0.5 0.1
Folding
buffer 5 10 8.8 - 0.1 0.5 -